Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards
ThinkAdvisor
Vial of insulin

Life Health > Health Insurance > Medicare Planning

New $35 Insulin Cost Cap Applies to More Medicare Enrollees

X
Your article was successfully shared with the contacts you provided.

What You Need to Know

  • The law's "cost-sharing" limit now helps the clients using their Medicare Part B benefits to pay for insulin.

The new federal cost-sharing limits for Medicare enrollees who use insulin could now help more of your clients.

The Inflation Reduction Act of 2022 imposed a $35-per-month cap on how much clients with Medicare Part D prescription drug coverage pay for their insulin starting Jan. 1.

Some clients with diabetes may get insulin through pumps purchased through Medicare Advantage plans or through the “Original Medicare” Part B outpatient hospital services and physician services plan. For them, the $35 cap took effect on July 1.

What It Means

Some clients with diabetes may now spend less on insulin.

Medicare Supplement Insurance

Some clients might use Original Medicare together with Medicare supplement insurance.

The Centers for Medicare and Medicaid Services, the agency that oversees Medicare, notes that the Medicare Part B deductible does not apply to spending on insulin.

Medicare Part B enrollees without Medicare supplement insurance could pay up to $35 in coinsurance per month for insulin.

But CMS says that any Medicare supplement insurance policies that pay Medicare Part B coinsurance amounts should pay a client’s monthly insulin coinsurance bills.

Resources

CMS has posted a collection of Medicare Part B insulin benefits guides on an Inflation Reduction Act information page.

An insulin delivery pen. Credit: Alex Flynn/Bloomberg


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.